Kornimate/medical-research-clean huggingface dataset:
daily self-weighing for obesity management in primary care

Conditions: Overweight and Obesity

Summary: many adults with obesity continue to gain weight even though they do not want to. this project will test the effects of a primary care intervention in which people with obesity receive an electronic scale and recommendations to weigh themselves daily. this will help us understand whether daily self-weighing might be a way to prevent continued weight gain.


Eligibility criteria:
inclusion criteria: * age 19-65 years * body mass index (bmi) 30 - 50 kg/m2 * receives care at one of the participating primary care clinics * resides in one location at least 5 days each week * possesses a smartphone with data plan * wi-fi or bluetooth internet connection in home exclusion criteria: * pregnancy or anticipating pregnancy during study duration. this is a weight loss study and weight gain/loss due to pregnancy and/or delivery would confound study results. additionally, weight loss is not recommended for pregnant women. * unwilling or unable to do any of the following: give informed consent, accept random assignment, attend five measurement assessments * likely to relocate and no longer be seen at uab primary care in the next 2 years * weight loss ≥5% of body weight in past 6 months (other than postpartum) * weight \>180 kg (396lbs) due to the limitation of the scale being used. * current participation in another weight loss study * bariatric surgery or revision in the past two years * prescription weight loss medications within the past 6 months * another household member already participating in the study * potential participants living farther than 50 miles driving distance from uab will be excluded from the study. it is expected that those living farther away will be more difficult to retain as study participants.

Keywords: weight management body weight behavioral weighing
assessment of cognitive functions in patients receiving whole brain radiotherapy in assiut university hospitals.

Conditions: Brain Tumors Treated by Whole Brain Radition

Summary: whole brain radiotherapy (wbrt) is widely used to manage brain metastases and primary brain tumors, but it frequently leads to cognitive decline, affecting patients' quality of life. cognitive impairments after wbrt can manifest in various domains, including memory, attention, executive function, and processing speed. these changes are attributed to direct radiation damage to neural tissues, particularly the hippocampus and white matter tracts, as well as secondary effects such as inflammation and vascular injury. existing literature reports that up to 30% of patients may experience significant cognitive deterioration after wbrt, with the degree of impairment influenced by factors like total radiation dose, fractionation schedule, patient age, and baseline cognitive function. despite these concerns, there is currently no standardized protocol for assessing cognitive changes in patients undergoing wbrt. hippocampal avoidance and neuroprotective agents like memantine have shown potential in mitigating cognitive side effects, but their implementation remains inconsistent. furthermore, routine cognitive assessments are not yet part of standard clinical practice, leading to a reactive rather than proactive approach to managing cognitive decline. this gap in early detection and standardized cognitive monitoring highlights the need for better methods to understand and manage the cognitive consequences of wbrt. without systematic assessment, cognitive impairments may go unrecognized until they significantly impact daily functioning, emphasizing the importance of addressing this issue to better support patients undergoing whole brain radiotherapy.


Eligibility criteria:
inclusion criteria: * • adult patients (18 years or older) * patients diagnosed with brain metastases or primary brain tumor requiring wbrt. * ability to provide informed consent. exclusion criteria: * • pre-existing severe cognitive impairments or psychiatric disorders unrelated to cancer treatment. * significant neurological conditions other than brain metastases. * patients unable or unwilling to provide informed consent.
ultrasonographic evaluation of fetal adrenal gland in cases of threatened preterm labor

Conditions: Preterm Labor

Summary: preterm birth continues to be a major public health problem with lasting family and societal repercussions. despite tremendous research effort, prevention strategies have failed, and the prevalence of preterm birth in the united states reached 12.3% in 2003. prematurity causes 70% of fetal/neonatal deaths. 11.4% of births are at \< 37 weeks' gestation. the rate of prematurity increases dramatically with the number of fetuses - singletons 10%; twins 54.9%; and triplets 93.6%


Eligibility criteria:
inclusion criteria: 1. singleton fetus less than 37 weeks of gestation 2. women diagnosed to having threatened preterm labor. 1. presence of uterine contraction (at least 4 in 20 min or 8 in 60 min ) 2. cervical effacement \<80 % 3. cervical dilatation \<1 cm exclusion criteria: 1. suspected fetal growth restriction, 2. maternal medical complications, 3. presence of fetal heart rate abnormalities at enrollment. 4. preterm premature rupture of membranes 5. placenta previa 6. lower urinary tract infection or genital infection 7. fetal congenital anomaly
comparison of thoracic paravertebral block and pectoral nerve block

Conditions: Thoracic Paravertebral Block; Video-assisted Thoracoscopic Surgery; Postoperative Analgesia

Summary: this study aims to compare the efficacy and safety of ultrasound-guidedpecs ii block with tpvb for postoperative analgesia after vats.

52 patients (asa i-iii) between 18 and 65 years of age, who were to undergo vats, were randomized and divided into two groups. (26 patients in each of the pecs and tpvb groups) thoracic paravertebral block was administered from two consecutive levels for tpvb group and a modified pectoral nerve block was performed in the pecs group. postoperative analgesia was provided by intravenous morphine infusion using a patient-controlled analgesia device. postoperative 24-hour total morphine consumption and duration of analgesia were the primary outcome measure. perioperative remifentanil use, visual analog scale values during at rest and coughing, time of the first analgesic request, and additional analgesic consumption were recorded.

Eligibility criteria:
inclusion criteria: * ages of 18-65 * patients who will undergo vats * asa i-ii-iii patients exclusion criteria: * patients with asa iv * clinically diagnosis of spinal or chest wall deformity or pathology * clinically known local anesthetic allergy * morbid obesity (body mass index\>40 kg m2) * clinically diagnosis of opioid, alcohol and substance dependence * clinically diagnosis of psychiatric disease * coagulopathy

Keywords: thoracic paravertebral block, pectoralis block, video-assisted thoracoscopic surgery, postoperative analgesia
[s,s]-reboxetine long term safety study in chronic painful diabetic peripheral neuropathy.

Conditions: Pain

Summary: the purpose of this study is to assess the long-term safety and tolerability of \[s,s\]-reboxetine in patients with chronic painful diabetic peripheral neuropathy


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 or 2 diabetes mellitus, with painful, distal, symmetrical, sensorimotor polyneuropathy * patients at screening must have a score \>/=40 mm on the pain visual analogue scale exclusion criteria: * patients with significant hepatic impairment * patients with other severe pain, that may impair the self-assessment of the pain due to dpn
testing new models of diabetes self-management to improve population health

Conditions: Diabetes Mellitus, Type 2

Summary: aim 1.1 to understand if diabetes self-management education and support (dsmes) improves diabetes-related outcomes among those with type 2 diabetes living in texas. aim 1.2 to examine how rurality affects study participation, engagement in, and effectiveness of different education interventions. these aims are based on a randomized controlled trial of different evidence-based diabetes self-management interventions.

a randomized controlled trial (rct) was conducted to assess the outcomes associated with different technological intervention approaches. this 3-arm rct assessed independent and combined interventions:

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (t2dm) - self-reported diagnosis by a health care provider * hba1c value greater than or equal to 7.5% * adults ages 25 years and older * all genders * have access to device (smartphone/tablet which meets ios 13 or above or similar system requirements/iphone 7 and above or android 6 and above) and internet in order to view online diabetes education content * ability to read and speak english * resides in texas exclusion criteria: * pregnant women * participation in ada-recognized or aade-accredited diabetes self-management education program lasting at least eight hours within previous six months * engagement with ada-recognized or aade-accredited smartphone application with certified diabetes educators providing tracking and health coaching within the previous six months * those diagnosed with any conditions listed below (determined by self-report): liver failure, end-stage renal disease (stage 4 or 5), congestive heart failure (grade c or d), organ transplant or bone marrow transplant, cystic fibrosis, malignant neoplasm or bone marrow transplant * criteria excludes individuals based on language. participants must be able to read and speak english. technology-based education and support (tbes) is available only in english.
fusing ultrasound and magnetic resonance imaging to intelligently plan highly conformal ablation thermal field for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: thermal ablation is an important minimally invasive treatment for hepatocellular carcinoma (hcc), but local tumor progression (ltp) after ablation restricts the efficacy and status of ablation technology and seriously threatens patient survival. insufficient coverage of thermal field is an important factor on the occurrence of ltp. current thermal field planning relies on tumor contours and doctor experience, and the safety margin is uniform. therefore, it cannot cope with the problem of insufficient coverage of thermal field caused by the different invasion capabilities of different tumors and different parts of the same tumor. this project intends to integratively analyze gray-scale ultrasound, contrast-enhanced ultrasound, magnetic resonance imaging and clinical information of hcc through deep canonical correlation analysis; summarize the prior knowledge of ltp risk factors in previous studies and perform conjoint analysis individual case data and common conclusions through knowledge graph; interpretatively predict the ltp risk and the high-risk ltp locations through link prediction; accurately predict the ablation safety margin required for different tumor parts through graph neural network, and achieve highly conformal thermal field planning based on different invasion capabilities to minimize the ltp risk of hcc. the project leverages tumor multi-modal imaging and prior knowledge as the entry point, performs highly conformal planning of the ablation thermal field through artificial intelligence technology, and provides a new method for precise ablation.


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed primary hepatocellular carcinoma 2. undergo curative ablation 3. with complete clinical information and pre- and post-operative imaging information exclusion criteria: 1. undergo palliative ablation 2. lack of clinical or imaging information 3. age less than 18 years
management of patent ductus in premature infants

Conditions: Cardiovascular Diseases; Defect, Congenital Heart; Ductus Arteriosus, Patent; Heart Diseases

Summary: to evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (pda) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in infants with persistent respiratory distress who were not treated early with indomethacin. two concurrent trials were performed.

background: the incidence of patent ductus arteriosus is higher in premature infants than in full-term infants and is highest in premature infants who have respiratory distress syndrome. it is generally agreed that intervention in an asymptomatic infant with a small left-to-right shunt is unnecessary, since the patent ductus almost invariably closes spontaneously and thus does not require surgery. a few infants will demonstrate signs of a large shunt during the course of respiratory distress syndrome. many of these infants will improve with medical management of congestive heart failure, but others require surgical closure. a third group of babies with respiratory distress have severe progressive pulmonary disease requiring ventilatory support. there was disagreement as to whether elimination of the patent ductus in these infants resulted in decreased mortality. a variety of therapeutic approaches was being used, and there was no convincing evidence of the superiority of one treatment over another. design narrative: trial a was a randomized, double-blind trial in which indomethacin plus usual medical therapy was compared with a placebo plus medical therapy. where this regimen was unsuccessful, the code was broken, and infants who received indomethacin were treated surgically. infants who had received placebo in trial a were entered, if there were no contraindications to indomethacin, into trial b. in trial b, infants were randomized to surgery or indomethacin therapy. those in whom indomethacin treatment was unsuccessful were treated surgically. the recruitment and intervention phase began in april 1979. all patients were enrolled by march 31, 1981, and followed for one year after enrollment.

Eligibility criteria:
boy and girl premature infants with patent ductus arteriosus. birth weight of 1,750 grams or less. admitted to participating institution within first 24 hours of life.
low field magnetic stimulation: imaging biomarkers in geriatric bipolar depression

Conditions: Bipolar Disorder; Bipolar Depression; Bipolar I Disorder; Bipolar II Disorder

Summary: the protocol involves functional magnetic resonance imaging acquisitions immediately before and after low field magnetic stimulation treatment on two separate days in a sham controlled, randomized trial, in order to assess the physiologic effects of low field magnetic stimulation on brain function in a geriatric population with bipolar depression.

in this study, the investigators will examine changes in brain activity from low field magnetic stimulation in subjects over the age of 50 with bipolar disorder who are currently depressed using functional magnetic resonance imaging. following screening visits, study procedures include two visits, at least two weeks apart, during which subjects will complete brief mood scales, undergo up to 15 minutes of imaging, receive 20 minutes of low field magnetic stimulation treatment, and then return to the scanner to undergo up to 15 minutes of imaging procedures. due to the crossover design, subjects receiving active treatment during the first visit will receive sham treatment during the second visit; subjects receiving sham treatment during the first visit will receive active treatment during the second visit. a follow-up phone call will occur at least two days after each imaging/treatment visit. the main endpoint of this study is the observation of changes in resting state functional magnetic resonance imaging activity in post-treatment acquisitions as compared to pre-treatment acquisitions.

Eligibility criteria:
inclusion criteria: 1. subjects will have a diagnosis of bipolar disorder type i or ii, current episode depressed as measure by a madrs ≥ 20. 2. subjects must be maintained on a stable dose of all psychotropic medications for a period of at least two weeks prior to screening. 3. subjects must be capable of providing informed consent. 4. subjects must permanently reside within a 2-hour drive of mclean hospital. 5. subjects must be currently seen by a provider (psychiatrist, therapist, pcp) whose practice is within a 2-hour drive of mclean hospital. exclusion criteria: 1. dangerous or active suicidal ideation, as measured by the c-ssrs (see "safety measures" section), and physician evaluation. 2. subjects meeting dsm-5 criteria for schizophrenia, schizoaffective disorder, or other psychotic disorders, or dementia. 3. current mania as defined by a score of ≥ 10 on the young mania rating scale at screening. 4. subject has an mmse score ≤ 24. 5. subject is pregnant or plans on becoming pregnant. 6. subject has recent history (within 7 days of screening) of ect or tms treatment. 7. subject has recent history of substance abuse (cannot meet dsm-5 criteria for substance abuse, no significant drug abuse within last 3 months, no history of dependence in last year, no drug use within last month, other than marijuana use). 8. subject has any contraindication for mri (i.e. presence of a pacemaker, neurostimulator, or metal in head or neck).

Keywords: geriatric low field magnetic stimulation antidepressant fmri mrs
ed intervention to reduce risky behaviors in drivers

Conditions: Alcohol Use

Summary: disability and death from injury remain a persistent problem in the u.s. and risk-taking behaviors are known to contribute to injury. healthy people 2010 set goals to reduce deaths caused by injury: "motor vehicle crashes are often predictable and preventable. increased use of seat belts and reductions in driving while impaired are two of the most effective means to reduce the risk of death and serious injury of occupants in motor vehicle crashes." one preventive strategy is to establish screening and intervention procedures that can be administered in the ed to young adults who have risky driving practices and problem drinking. goal: the specific aim of this prospective, randomized controlled trial is to test the effectiveness of a brief intervention to limit risky driving behaviors (risky driving practices, lack of seat belt compliance) and problem drinking in drivers during an ed visit. in addition, the trial will result in a benefit-cost analysis from the perspectives of both society as a whole and hospitals in particular. methods: young adults 18 to 44 years will be screened for problem drinking and risky driving practices during an ed visit. subjects who screen positive for problem drinking and risky driving will be randomized to one of three groups: no contact control group (ncg: after informed consent, subjects receive no screening or intervention until 12 months after injury). contact control group (ccg: subjects screened at baseline and every three months for 12 months but no intervention), and a brief intervention group (big: subjects receive screening and brief intervention with data collection points every three months for 12 months). a total of 133 subjects per group (n=400) will be enrolled. the intervention will consist of a 20 minute nurse visit in the ed and a booster intervention at 7-10 days after ed discharge. all subjects will be telephoned at 3, 6, 9, and 12 months by interviewers blinded to condition. outcomes of interest include reported alcohol use, risky driving behaviors, driving citations, adverse health outcomes, and costs (health care utilization, property damage, travel delays, lost work productivity, criminal justice expenses, and monetarized adverse health outcomes). analysis: power analysis suggests that 133 subjects in each arm of the trial will have sufficient power to detect a difference of the main outcome variables of interest. a variety of regression techniques, including individual growth curve modeling and event history analysis, will be used to test the proposed hypotheses.


Eligibility criteria:
inclusion criteria: screen positive for a drinking problem in the ed exclusion criteria: * \ 44years old
chemoradiotherapy with or without sintilimab in limited-stage sclc

Conditions: Small Cell Lung Cancer Limited Stage

Summary: the study is a prospective, multi-center, open-label, randomized, and controlled phase ii clinical trial.


Eligibility criteria:
inclusion criteria: 1. histologically/cytologically confirmed diagnosis of sclc. 2. radiologically (including brain ct/mri, chest and abdomen contrasted ct and bone scintigraphy. pet/ct is recommended) confirmed limited-stage. 3. patients should be ≥ 18 years old. 4. ecog performance status of 0-1 (karnofsky performance status ≥ 80). 5. with adequate cardiac, pulmonary, bone marrow, hepatic and renal function. 6. with weight loss no more than 10% within 6 months before diagnosis. 7. informed consent must be signed. exclusion criteria: 1. histology confirmed the mixed nsclc components; 2. other primary malignant tumors appeared within 5 years before the first administration of the study drug, except for locally curable malignant tumors after radical treatment (such as basal or squamous cell skin cancer, superficial bladder cancer or prostate, cervical or breast carcinoma in situ, etc.); 3. any disease or condition contraindicated by radiotherapy or chemotherapy; 4. malignant pleural effusion and pericardial effusion; 5. pregnant and lactating women; 6. history of idiopathic pulmonary fibrosis (ipf), including pneumonia and organic pneumonia; 7. received live vaccination within 28 days before the first administration of the study drug; 8. 28 days prior to the first administration of the study drug, he participated in any other drug clinical trials or is undergoing other clinical trials. 9. have received any antibody / drug (including pd-1, pdl1, ctla4, tim3, lag3, etc.) targeting t-cell co regulatory protein (immunocheckpoint). 10. the investigator believes that the subject's complications or other circumstances may affect the compliance with the protocol or may not be suitable for the study.

Keywords: radiotherapy chemotherapy immunotherapy pd-1 inhibitor lung cancer small cell limited-stage
study of azithromycin intravenous formulation against pelvic inflammatory disease (pid) in japan

Conditions: Pelvic Inflammatory Disease

Summary: azithromycin had a potent in vitro activities and broad spectrum from typical and atypical bacteria to anaerobes. azithromycin intravenous formulation demonstrated high efficacy and eradication rate in the western clinical trials. development of azithromycin intravenous formulation would bring the clinical benefit to patients with pelvic inflammatory disease (pid) in japan.


Eligibility criteria:
inclusion criteria: both of following symptoms should be observed. * lower abdominal pain and/or lower abdominal tenderness. * hypochondrial pain and/or hypochondrial tenderness (tenderness of uterus or adnexa of uterus). exclusion criteria: known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides. hepatic dysfunction (ast, alt, total bilirubin \> 3 times institutional normal).
hss covid-19 antibody serology among surgeons & anesthesiologists

Conditions: COVID

Summary: the goal of this study is to understand the infectious exposure of sars-coronavirus 2 (sars-cov2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of covid-19 illness.


Eligibility criteria:
inclusion criteria: * accredited to practice at hss * all anesthesiology and surgery faculty * all anesthesia and orthopedic surgery fellows * all orthopedic surgery residents exclusion criteria: • refusal to participate in either of the interventions at either of the timepoints of interest